Patents by Inventor Ko Rii
Ko Rii has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220265698Abstract: Provided is a composition capable of enhancing the effect of an antibody drug such as an immune checkpoint inhibitor, etc. A ?-glucan is used as an active ingredient of a composition for enhancing the effect of an antibody drug. This composition is used suitably for antibody drugs that have an effect of suppressing growth of cancer via immune checkpoint inhibition; e.g., antibody drugs including a monoclonal antibody to PD-L1.Type: ApplicationFiled: September 10, 2020Publication date: August 25, 2022Applicants: AUREO CO., LTD., NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENTInventors: Ko RII, Masayuki FUJINO, Yukiko MORIYA
-
Publication number: 20220249417Abstract: The object of the invention is to provide a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor. Provided is a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor comprising 5-aminolevulinic acids (ALAs) as the active ingredient.Type: ApplicationFiled: February 28, 2022Publication date: August 11, 2022Inventors: Tohru Tanaka, Hidenori Ito, Ko Rii
-
Patent number: 11266619Abstract: The object of the invention is to provide a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor. Provided is a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor comprising 5-aminolevulinic acids (ALAs) as the active ingredient.Type: GrantFiled: November 28, 2018Date of Patent: March 8, 2022Assignees: SBI Pharmaceuticals Co., Ltd., National Center for Child Health and DevelopmentInventors: Tohru Tanaka, Hidenori Ito, Ko Rii
-
Publication number: 20200297674Abstract: The object of the invention is to provide a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor. Provided is a pharmaceutical composition for enhancing the antitumor effect by an immune checkpoint inhibitor comprising 5-aminolevulinic acids (ALAs) as the active ingredient.Type: ApplicationFiled: November 28, 2018Publication date: September 24, 2020Inventors: Tohru Tanaka, Hidenori Ito, Ko Rii
-
Patent number: 9937138Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.Type: GrantFiled: March 9, 2016Date of Patent: April 10, 2018Assignees: National Center for Child Health and Development, SBI Pharmaceuticals Co., Ltd.Inventors: Ko Rii, Kiwamu Takahashi, Naomi Haga, Fuminori Abe, Tohru Tanaka, Motowo Nakajima, Hidenori Ito
-
Patent number: 9901558Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.Type: GrantFiled: March 9, 2016Date of Patent: February 27, 2018Assignees: National Center for Child Health and Development, SBI Pharmaceuticals Co., Ltd.Inventors: Ko Rii, Kiwamu Takahashi, Naomi Haga, Fuminori Abe, Tohru Tanaka, Motowo Nakajima, Hidenori Ito
-
Patent number: 9801929Abstract: An object of the present invention is to provide a drug and a method for effectively inducing donor-specific immune tolerance in a recipient in transplantation therapy. A complex of an siRNA for a costimulatory factor and schizophyllan is delivered to a Dectin-1 expressing cell which specifically recognizes schizophyllan to regulate the function of the Dectin-1 expressing cell, and therefore can induce immunosuppression effect as well as induce immune tolerance effectively.Type: GrantFiled: July 13, 2012Date of Patent: October 31, 2017Assignee: Napajen Pharma, Inc.Inventors: Ko Rii, Kazuo Sakurai, Masakazu Kobayashi, Hironori Ando, Sadaharu Higuchi, Shiro Takahara
-
Patent number: 9713636Abstract: A highly stable nucleic acid-polysaccharide complex of an siRNA and schizophyllan is formed by adding polydeoxyadenine in which at least part of the phosphodiester link portion is phosphorothioated to an siRNA and allowing the siRNA and schizophyllan to form a complex.Type: GrantFiled: February 15, 2012Date of Patent: July 25, 2017Assignee: NAPAJEN PHARMA, INC.Inventors: Ko Rii, Kazuo Sakurai, Masakazu Kobayashi, Hironori Ando, Sadaharu Higuchi, Shiro Takahara
-
Publication number: 20170202210Abstract: Provided is an organ preservation solution for use in transplantation, which is capable of effectively preventing the occurrence of ischemia-reperfusion injury. Prepared is an organ preservation solution comprising a mixture of the following components: (a) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, and D-glucose; (b) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, glycine, and D-glucose; (c) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, L-cysteine, glycine, and D-glucose; or (d) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, L-cysteine, glycine, an iron compound, and D-glucose.Type: ApplicationFiled: February 24, 2015Publication date: July 20, 2017Inventors: Tohru TANAKA, Motowo NAKAJIMA, Urara OTA, Hidenori ITO, Ko RII
-
Patent number: 9399029Abstract: An object of the present invention is to provide a regulatory dendritic cell inducing agent applicable to the treatment of immune disease as well as an immune tolerance inducing agent such as a preventive and/or therapeutic agent for allergic disease and a preventive and/or therapeutic agent for autoimmune disease, both of which are safe and have the mechanism of action different from that of conventional drugs. As a means for achieving the above object, an immune tolerance inducing agent comprising 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of the 5-ALA or the derivative and an iron compound as active ingredients is prepared. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.Type: GrantFiled: July 3, 2013Date of Patent: July 26, 2016Assignees: SBI Pharmaceuticals Co., Ltd., National Center for Child Health and DevelopmentInventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Naomi Haga, Kiwamu Takahashi, Hidenori Ito, Ko Rii
-
Publication number: 20160206582Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.Type: ApplicationFiled: March 9, 2016Publication date: July 21, 2016Applicants: SBI Pharmaceuticals Co., Ltd., National Center for Child Health and DevelopmentInventors: Ko RII, Kiwamu TAKAHASHI, Naomi HAGA, Fuminori ABE, Tohru TANAKA, Motowo NAKAJIMA, Hidenori ITO
-
Publication number: 20160184250Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.Type: ApplicationFiled: March 9, 2016Publication date: June 30, 2016Applicants: SBI Pharmaceuticals Co., Ltd., National Center for Child Health and DevelopmentInventors: Ko RII, Kiwamu TAKAHASHI, Naomi HAGA, Fuminori ABE, Tohru TANAKA, Motowo NAKAJIMA, Hidenori ITO
-
Patent number: 9314443Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.Type: GrantFiled: September 12, 2012Date of Patent: April 19, 2016Assignees: National Center for Child Health and Development, SBI Pharmaceuticals Co., Ltd.Inventors: Ko Rii, Kiwamu Takahashi, Naomi Haga, Fuminori Abe, Tohru Tanaka, Motowo Nakajima, Hidenori Ito
-
Publication number: 20150174090Abstract: An object of the present invention is to provide a regulatory dendritic cell inducing agent applicable to the treatment of immune disease as well as an immune tolerance inducing agent such as a preventive and/or therapeutic agent for allergic disease and a preventive and/or therapeutic agent for autoimmune disease, both of which are safe and have the mechanism of action different from that of conventional drugs. As a means for achieving the above object, an immune tolerance inducing agent comprising 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of the 5-ALA or the derivative and an iron compound as active ingredients is prepared. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.Type: ApplicationFiled: July 3, 2013Publication date: June 25, 2015Applicants: SBI PHARMACEUTICALS CO., LTD., National Center for Child Health and DevelopmentInventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Naomi Haga, Kiwamu Takahashi, Hidenori Ito, Ko Rii
-
Publication number: 20140294869Abstract: An object of the present invention is to provide a drug and a method for effectively inducing donor-specific immune tolerance in a recipient in transplantation therapy. A complex of an siRNA for a costimulatory factor and schizophyllan is delivered to a Dectin-1 expressing cell which specifically recognizes schizophyllan to regulate the function of the Dectin-1 expressing cell, and therefore can induce immunosuppression effect as well as induce immune tolerance effectively.Type: ApplicationFiled: July 13, 2012Publication date: October 2, 2014Inventors: Ko Rii, Kazuo Sakurai, Masakazu Kobayashi, Hironori Ando, Sadaharu Higuchi, Shiro Takahara
-
Publication number: 20140249217Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.Type: ApplicationFiled: September 12, 2012Publication date: September 4, 2014Inventors: Ko Rii, Kiwamu Takahashi, Naomi Haga, Fuminori Abe, Tohru Tanaka, Motowo Nakajima, Hidenori Ito
-
Publication number: 20140128448Abstract: An object of the present invention is to provide a highly stable nucleic acid-polysaccharide complex of an siRNA and schizophyllan. A nucleic acid-polysaccharide complex is formed by adding polydeoxyadenine in which at least part of the phosphodiester link portion is phosphorothioated to an siRNA and allowing the siRNA and schizophyllan to form a complex.Type: ApplicationFiled: February 15, 2012Publication date: May 8, 2014Applicant: NAPAJEN PHARMA, INC.Inventors: Ko Rii, Kazuo Sakurai, Masakazu Kobayashi, Hironori Ando, Sadaharu Higuchi, Shiro Takahara